Given that abnormal expression of EZH2 plays an essential role in tumor cell proliferation, invasion, metastasis, and drug resistance [93], targeted inhibition of EZH2/PRC2 is considered an attractive target for cancer therapy. Here, EZH2 is linked to cancer.